A recent Indian evidence-based review highlighted recommendations  from a multidisciplinary team of paediatricians on the appropriate use of  acid-reducing medications (ARMs) in children.
    Gastric acid-reducing medications  (ARMs), including H2 blockers and PPIs, are essential for treating various  gastrointestinal conditions in pediatric care. However,  concerns over safety and widespread off-label use persist, especially in  younger children, due to lack of clear, practice-based prescribing guidelines. 
    The Evidence-based review from  Multidisciplinary team of Pediatricians on the use of gastric Acid-reducing  medications in Children: Indian Perspectives (EMPACIP) study was undertaken to  address these gaps by offering clear, evidence-based recommendations to guide  appropriate ARM use and support informed prescribing in pediatric care. 
    Twenty-four pediatric  specialists, including neonatologists, general pediatricians, pediatric  gastroenterologists,  pediatric  nephrologists, a pediatric hepatologist, a pediatric pulmonologist, and a  pediatric intensivist from across India, conducted a structured literature review and  collaboratively evaluated ARM use and current practices. 
    They defined and assessed the severity  of drug-induced dyspepsia using the ‘5-point Likert Scale Dyspepsia Severity Scale' via the  Mentimeter platform. Among the various drug classes, NSAIDs and  their combinations were identified as the most common cause of drug-induced  dyspepsia, followed by Antibiotics like Amoxicillin/Clavulanic Acid,  Azithromycin, Cefuroxime, Steroids like Prednisolone, and Nutritional  supplements like Iron and Zinc supplements. 
    The following are the  recommendations provided:
    - PPIs should be limited to confirmed GERD or erosive esophagitis,  avoided in NICUs, and used in infants under 1 year only when clearly needed. 
- In cases of potential kidney injury, replace  PPIs with H2RAs like ranitidine or famotidine, and perform routine urine tests  if PPI use exceeds one week.
- In neonates and infants, ARMs should only be  used for symptomatic reflux, not for apnea alone, with H2RAs like ranitidine  preferred for stress ulcer prophylaxis (SUP).
- H2RAs like ranitidine provide rapid symptom  relief, making them suitable for on-demand use, managing nocturnal acid  breakthrough, and serving as step-down or rescue therapy from PPIs. 
- ARM therapy does not consistently improve asthma  outcomes and should be reserved for asthmatic children with symptomatic GERD,  with H2RAs like ranitidine being the safer choice. 
- ARMs should be used for drug-induced dyspepsia  only when symptoms occur, stopped within 72 hours, with H2RAs like ranitidine  preferred for faster relief.
These  findings aim to guide primary care practitioners in adopting evidence-based ARM  practices, serving as a resource for current and future paediatricians to  improve patient care.
    Reference: Pai UA, Ravishankar AV, Bharadia L, H R S,  Wadhwa A, Prajapati B, C J, Mittal G, Belsare H, Anand K, Narayanan K,  Furniturewala K, Sanklecha M, Suresh Kumar MV, Bhattacharya P, N P, Jog P,  Wazir S, Soans ST, Manikanti SS, Roy S, Bhattacharyya S, Bansal U, Goswami V.  Evidence-Based Review by a Multidisciplinary Team of Pediatricians on the Use  of Gastric Acid-Reducing Medications in Children: Indian Perspectives. Cureus.  2025 May 7;17(5):e83653. doi: 10.7759/cureus.83653. PMID: 40486365; PMCID: PMC12143190.
 
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.